BioCentury | Mar 6, 2021
Product Development
March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura
...Lorbrena lorlatinib as a first-line treatment for ALK-positive non-small cell lung cancer. The inhibitor of ALK...
...and ROS1 previously had accelerated approval in second- and third-line settings following treatment with other ALK...
...and ROS1 previously had accelerated approval in second- and third-line settings following treatment with other ALK...